Tarsus Pharmaceuticals (TARS) Projected to Post Quarterly Earnings on Tuesday

Tarsus Pharmaceuticals (NASDAQ:TARS) is anticipated to post its Q4 2025 results before the market opens on Tuesday, February 24th. Analysts expect Tarsus Pharmaceuticals to post earnings of ($0.19) per share for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Tuesday, February 24, 2026 at 8:00 AM ET.

Tarsus Pharmaceuticals Stock Down 3.9%

TARS opened at $60.78 on Tuesday. The company has a debt-to-equity ratio of 0.22, a quick ratio of 4.25 and a current ratio of 4.29. The company has a market capitalization of $2.58 billion, a PE ratio of -30.09, a P/E/G ratio of 0.88 and a beta of 0.57. The stock’s fifty day moving average is $73.85 and its 200-day moving average is $67.36. Tarsus Pharmaceuticals has a one year low of $38.51 and a one year high of $85.25.

Insider Activity at Tarsus Pharmaceuticals

In related news, insider Dianne C. Whitfield sold 7,397 shares of Tarsus Pharmaceuticals stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $80.10, for a total value of $592,499.70. Following the completion of the sale, the insider owned 38,958 shares of the company’s stock, valued at approximately $3,120,535.80. The trade was a 15.96% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Bobak R. Azamian sold 6,000 shares of the company’s stock in a transaction dated Wednesday, December 24th. The stock was sold at an average price of $82.51, for a total value of $495,060.00. Following the sale, the chief executive officer owned 857,991 shares of the company’s stock, valued at approximately $70,792,837.41. This trade represents a 0.69% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 8.97% of the company’s stock.

Institutional Trading of Tarsus Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the business. Deep Track Capital LP lifted its holdings in shares of Tarsus Pharmaceuticals by 71.4% during the third quarter. Deep Track Capital LP now owns 3,000,000 shares of the company’s stock worth $178,290,000 after buying an additional 1,250,000 shares during the last quarter. Morgan Stanley raised its stake in Tarsus Pharmaceuticals by 6.7% during the 4th quarter. Morgan Stanley now owns 2,040,742 shares of the company’s stock valued at $167,096,000 after purchasing an additional 128,340 shares during the last quarter. Invesco Ltd. raised its stake in Tarsus Pharmaceuticals by 0.9% during the 3rd quarter. Invesco Ltd. now owns 937,006 shares of the company’s stock valued at $55,686,000 after purchasing an additional 8,505 shares during the last quarter. Adage Capital Partners GP L.L.C. boosted its holdings in Tarsus Pharmaceuticals by 6.5% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 543,000 shares of the company’s stock valued at $21,997,000 after purchasing an additional 33,000 shares during the period. Finally, Bank of America Corp DE grew its position in Tarsus Pharmaceuticals by 15.0% in the 3rd quarter. Bank of America Corp DE now owns 536,023 shares of the company’s stock worth $31,856,000 after purchasing an additional 69,743 shares during the last quarter. Institutional investors own 90.01% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on TARS shares. HC Wainwright raised their price objective on shares of Tarsus Pharmaceuticals from $72.00 to $88.00 and gave the company a “neutral” rating in a research report on Monday, October 20th. The Goldman Sachs Group restated a “neutral” rating and set a $68.00 target price on shares of Tarsus Pharmaceuticals in a report on Thursday, February 5th. Zacks Research raised Tarsus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Friday, January 23rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research note on Thursday, January 22nd. Finally, Wall Street Zen upgraded Tarsus Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Two analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Tarsus Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $82.29.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.